Nykode Therapeutics ASA (NYKD) — Capital Reinvestment Ratio
Nykode Therapeutics ASA (NYKD) has a Capital Reinvestment Ratio of 0.15x as of March 2022, meaning it reinvests 0% of its operating cash flow (Nkr96.14 Million) in capital expenditures (Nkr14.06 Million). See NYKD equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nykode Therapeutics ASA Capital Reinvestment Ratio (2020–2021)
This chart tracks Nykode Therapeutics ASA's Capital Reinvestment Ratio across 2 annual periods. Check NYKD capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Nykode Therapeutics ASA (2020–2021)
Year-by-year Capital Reinvestment Ratio for Nykode Therapeutics ASA from 2020 to 2021. For live market cap and broader valuation context, see Nykode Therapeutics ASA market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (NOK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.75x | Nkr1.16 Million | Nkr871.00K | ▲ +137214.0% |
| 2020 | 0.00x | Nkr180.27 Million | Nkr99.00K | — |